シロスタゾールの抗血小板作用(神経内科学教室岩田誠教授退任記念特別号)

概要

論文の詳細を見る
To evaluate the antiplatelet effects of cilostazol, 7 patients (6 men and 1 woman, mean age: 72) with carotid stenosis were administered 200 mg/day of cilostazol, and platelet aggregation and platelet activation markers were measured both before and after administration. Platelet aggregation was measured with the turbidimetric method, and platelet activation markers, including PAC-1 binding, p-selectin expression, and platelet-derived microparticle formation (PDMP), were measured by flow cytometry. We also measured the inhibitory effects of cilostazol on platelet aggregation and platelet activation induced by adenosine diphosphate (ADP), arachidonic acid and collagen, in vitro. PAC-1 binding and p-selectin expression were decreased, and platelet aggregation induced by ADP was nonsignificantly suppressed with cilostazol. On the other hand, cilostazol inhibited platelet aggregation and activation equally in a dose-dependent manner in vitro. It was suggested from these results that the improvement of endothelial function might be the reason that platelet activation markers were more suppressed than platelet aggregation ex vivo with cilostazol.
2008-02-25